Valeo Pharma Inc
TSX:VPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Valeo Pharma Inc
Long-Term Investments
Valeo Pharma Inc
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valeo Pharma Inc
TSX:VPH
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Long-Term Investments
$37.2m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Long-Term Investments
CA$79.5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Valeo Pharma Inc
Glance View
Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. The company is headquartered in Kirkland, Quebec and currently employs 100 full-time employees. The company went IPO on 2019-02-20. The firm acquires or in-licenses brand and hospital specialty products for sale in Canada. The firm is focused on four therapeutic areas, which includes respiratory, oncology, specialty products and neurology. Its respiratory product is Enerzair breezhaler and Atectura breezhaler; its oncology product is Yondelis; its specialty product includes Redesca, Ametop Gel, and M-Eslon and its neurology product is Onstryv. The firm has eight marketed brands and four additional products. Its wholly owned subsidiary is VPI Pharmaceuticals Inc.(VPI).
